Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18

Section 11

Discontinuance

Cite as Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations, SOR/2022-18, s. 11 · current to July 24, 2025 · regulation last amended February 27, 2022

Statute Watch

Get an alert when a bill in Parliament would change this section, and every time it moves.

The text

If a holder of a COVID-19 medical device authorization discontinues, in whole or in part, the clinical trial for which the authorization has been issued, the holder must, without delay, (a) notify the Minister, in writing, of the discontinuance and the reasons for it; (b) inform all qualified investigators, in writing, of the discontinuance and the reasons for it and advise them, in writing, of any potential risks to the health of clinical trial subjects, users or other persons; and (c) in respect of each clinical trial site at which the trial is discontinued, stop the importation or sale of the device as of the date of the discontinuance and take all reasonable measures to ensure the recovery of all unused quantities of the device that have been sold.
Read the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations on the Justice Laws Website ↗

Made under Food and Drugs Act, R.S.C. 1985, c. F-27; Patent Act, R.S.C. 1985, c. P-4.

Bills in Parliament that would change this section 0

No bill we hold would amend or repeal this section.